Physician profile
Perry J Foreman
NPI 1346231677
$194,300.12
in general payments reported to CMS, 2019-2025
49 companies · $16K in 2025
The $16K reported for 2025 was more than what 92% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $42K · 2021: $23K · 2022: $18K · 2023: $48K · 2024: $24K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $40K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Food and Beverage: $7,166 · Travel and Lodging: $6,553 · Consulting Fee: $5,273 · Education: $39.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $40,300.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,600.00 |
| Food and Beverage | $7,165.83 |
| Travel and Lodging | $6,553.05 |
| Consulting Fee | $5,272.50 |
| Education | $39.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $81,187.95 | 2020-2025 | Xcopri |
| Ucb, INC. | $54,626.76 | 2019-2025 | Nayzilam, Briviact, Fintepla |
| Eisai INC. | $17,771.07 | 2019-2023 | |
| Livanova USA, INC. | $9,813.06 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Sunovion Pharmaceuticals INC. | $9,582.43 | 2019-2022 | |
| Catalyst Pharmaceuticals, INC. | $8,842.11 | 2023-2024 | Fycompa |
| Neurelis, INC. | $3,817.68 | 2020-2024 | Valtoco |
| Ceribell, INC. | $1,982.90 | 2023-2025 | Ceribell Rapid Response Eeg, Pocket Eeg Device |
| Abbvie INC. | $1,559.55 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $785.42 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $778.08 | 2022-2025 | |
| Biogen, INC. | $319.88 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Teva Pharmaceuticals USA, INC. | $279.17 | 2019-2025 | Austedo Xr, Ajovy |
| Greenwich Biosciences, INC. | $239.17 | 2019-2021 | |
| Neuropace, INC. | $232.70 | 2019-2020 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perry Foreman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.